EdiGene snags about $67m Series B
Beijing-based EdiGene, Inc., a developer of genome editing technologies, has raised about $67 million in Series B financing.
Beijing-based EdiGene, Inc., a developer of genome editing technologies, has raised about $67 million in Series B financing.
Copyright PEI Media
Not for publication, email or dissemination